Literature DB >> 19794044

Characteristics of Candida albicans biofilms grown in a synthetic urine medium.

Priya Uppuluri1, Hemamalini Dinakaran, Derek P Thomas, Ashok K Chaturvedi, Jose L Lopez-Ribot.   

Abstract

Urinary tract infections (UTIs) are the most common type of nosocomial infection, and Candida albicans is the most frequent organism causing fungal UTIs. Presence of an indwelling urinary catheter represents a significant risk factor for UTIs. Furthermore, these infections are frequently associated with the formation of biofilms on the surface of these catheters. Here, we describe the characterization of C. albicans biofilms formed in vitro using synthetic urine (SU) medium and the frequently used RPMI medium and compare the results. Biofilms of C. albicans strain SC5314 were formed in 96-well microtiter plates and on silicon elastomer pieces using both SU and RPMI media. Biofilm formation was monitored by microscopy and a colorimetric XTT [2,3-bis(2-methoxy-4-nitro-5-sulfophenyl)-2H-tetrazolium-5-carboxanilide] reduction assay. As in biofilms grown in RPMI medium, time course studies revealed that biofilm formation using SU medium occurred after an initial adherence phase, followed by growth, proliferation, and maturation. However, microscopy techniques revealed that the architectural complexity of biofilms formed in SU medium was lower than that observed for those formed using RPMI medium. In particular, the level of filamentation of cells within the biofilms formed in SU medium was diminished compared to those in the biofilms grown in RPMI medium. This observation was also corroborated by expression profiling of five filamentation-associated genes using quantitative real-time reverse transcriptase PCR. Sessile C. albicans cells were resistant to fluconazole and amphotericin B, irrespective of the medium used to form the biofilms. However, caspofungin exhibited potent in vitro activity at therapeutic levels against C. albicans biofilms grown in both SU and RPMI media.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19794044      PMCID: PMC2786631          DOI: 10.1128/JCM.01377-09

Source DB:  PubMed          Journal:  J Clin Microbiol        ISSN: 0095-1137            Impact factor:   5.948


  32 in total

Review 1.  Candida biofilms: antifungal resistance and emerging therapeutic options.

Authors:  Duncan M Kuhn; Mahmoud A Ghannoum
Journal:  Curr Opin Investig Drugs       Date:  2004-02

2.  Transcriptional profiling of the early stages of germination in Candida albicans by real-time RT-PCR.

Authors:  Mika Toyoda; Tamaki Cho; Hidenori Kaminishi; Masayuki Sudoh; Hiroji Chibana
Journal:  FEMS Yeast Res       Date:  2004-12       Impact factor: 2.796

Review 3.  Candida biofilms on implanted biomaterials: a clinically significant problem.

Authors:  Gordon Ramage; José Pedro Martínez; José Luis López-Ribot
Journal:  FEMS Yeast Res       Date:  2006-11       Impact factor: 2.796

Review 4.  Candida albicans biofilm development, modeling a host-pathogen interaction.

Authors:  Jeniel Nett; David Andes
Journal:  Curr Opin Microbiol       Date:  2006-06-30       Impact factor: 7.934

5.  Unique aspects of gene expression during Candida albicans mating and possible G(1) dependency.

Authors:  Rui Zhao; Karla J Daniels; Shawn R Lockhart; Kathleen M Yeater; Lois L Hoyer; David R Soll
Journal:  Eukaryot Cell       Date:  2005-07

6.  In vitro pharmacodynamic properties of three antifungal agents against preformed Candida albicans biofilms determined by time-kill studies.

Authors:  Gordon Ramage; Kacy VandeWalle; Stefano P Bachmann; Brian L Wickes; José L López-Ribot
Journal:  Antimicrob Agents Chemother       Date:  2002-11       Impact factor: 5.191

7.  Efg1p, an essential regulator of morphogenesis of the human pathogen Candida albicans, is a member of a conserved class of bHLH proteins regulating morphogenetic processes in fungi.

Authors:  V R Stoldt; A Sonneborn; C E Leuker; J F Ernst
Journal:  EMBO J       Date:  1997-04-15       Impact factor: 11.598

8.  Biofilm formation by the fungal pathogen Candida albicans: development, architecture, and drug resistance.

Authors:  J Chandra; D M Kuhn; P K Mukherjee; L L Hoyer; T McCormick; M A Ghannoum
Journal:  J Bacteriol       Date:  2001-09       Impact factor: 3.490

Review 9.  Candida infections of medical devices.

Authors:  Erna M Kojic; Rabih O Darouiche
Journal:  Clin Microbiol Rev       Date:  2004-04       Impact factor: 26.132

10.  Synergistic effect of calcineurin inhibitors and fluconazole against Candida albicans biofilms.

Authors:  Priya Uppuluri; Jeniel Nett; Joseph Heitman; David Andes
Journal:  Antimicrob Agents Chemother       Date:  2008-01-07       Impact factor: 5.191

View more
  22 in total

1.  Effects of fluconazole, amphotericin B, and caspofungin on Candida albicans biofilms under conditions of flow and on biofilm dispersion.

Authors:  Priya Uppuluri; Anand Srinivasan; Anand Ramasubramanian; Jose L Lopez-Ribot
Journal:  Antimicrob Agents Chemother       Date:  2011-04-25       Impact factor: 5.191

2.  Rat indwelling urinary catheter model of Candida albicans biofilm infection.

Authors:  Jeniel E Nett; Erin G Brooks; Jonathan Cabezas-Olcoz; Hiram Sanchez; Robert Zarnowski; Karen Marchillo; David R Andes
Journal:  Infect Immun       Date:  2014-09-02       Impact factor: 3.441

3.  Host contributions to construction of three device-associated Candida albicans biofilms.

Authors:  Jeniel E Nett; Robert Zarnowski; Jonathan Cabezas-Olcoz; Erin G Brooks; Jörg Bernhardt; Karen Marchillo; Deane F Mosher; David R Andes
Journal:  Infect Immun       Date:  2015-09-14       Impact factor: 3.441

4.  Candida tropicalis Biofilms: Biomass, Metabolic Activity and Secreted Aspartyl Proteinase Production.

Authors:  Melyssa Negri; Sónia Silva; Isis Regina Grenier Capoci; Joana Azeredo; Mariana Henriques
Journal:  Mycopathologia       Date:  2015-11-16       Impact factor: 2.574

5.  Dynamics of Mixed- Candida Species Biofilms in Response to Antifungals.

Authors:  G Vipulanandan; M Herrera; N P Wiederhold; X Li; J Mintz; B L Wickes; D Kadosh
Journal:  J Dent Res       Date:  2017-08-29       Impact factor: 6.116

6.  Antifungal activity of a β-peptide in synthetic urine media: Toward materials-based approaches to reducing catheter-associated urinary tract fungal infections.

Authors:  Namrata Raman; Myung-Ryul Lee; Angélica de L Rodríguez López; Sean P Palecek; David M Lynn
Journal:  Acta Biomater       Date:  2016-07-12       Impact factor: 8.947

7.  On-demand release of Candida albicans biofilms from urinary catheters by mechanical surface deformation.

Authors:  Stacey A Maskarinec; Zehra Parlak; Qing Tu; Vrad Levering; Stefan Zauscher; Gabriel P López; Vance G Fowler; John R Perfect
Journal:  Biofouling       Date:  2018-06-13       Impact factor: 3.209

8.  An IMS/ATP Assay for the Detection of Mycobacterium tuberculosis in Urine.

Authors:  Dawn M Hunter; Daniel V Lim
Journal:  Tuberc Res Treat       Date:  2012-05-09

9.  Candida biofilms and the host: models and new concepts for eradication.

Authors:  Hélène Tournu; Patrick Van Dijck
Journal:  Int J Microbiol       Date:  2011-11-14

10.  A micro-extraction technique using a new digitally controlled syringe combined with UHPLC for assessment of urinary biomarkers of oxidatively damaged DNA.

Authors:  Berta Mendes; Pedro Silva; Fernando Aveiro; Jorge Pereira; José S Câmara
Journal:  PLoS One       Date:  2013-03-06       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.